Welcome to the Dominantly Inherited Alzheimer's Network (DIAN) Expanded Registry
The DIAN Expanded Registry at the Washington University School of Medicine is collecting contact information for ongoing studies in Autosomal Dominant Alzheimer's disease. The DIAN research studies aim to find the changes that cause Alzheimer’s disease and determine if new investigational drugs can improve cognitive health.
Autosomal Dominant Alzheimer's disease (ADAD) is a rare form of Alzheimer's disease that typically causes memory loss and dementia in the 30's to 50's. ADAD has a strong family history with approximately 50% of descendants being affected by the disease. ADAD is caused by mutations in one of three genes and there are genetic tests available. ADAD is very rare as it makes up only 1% of the total cases of Alzheimer's disease. For extensive information on ADAD, see the Alzforum focus section on Dominantly Inherited Alzheimer's disease.
The DIAN Expanded Registry is an international registry for Autosomal Dominant Alzheimer's disease (ADAD) drug trials. The goal of the DIAN Expanded Registry is to collect contact information from eligible participants interested in ADAD trials to test new drugs, and/or the DIAN observational study. The DIAN Expanded Registry is managed by the DIAN Therapeutic Trials Unit at Washington University School of Medicine in St. Louis. The DIAN Expanded Registry is funded in part by a grant from the Alzheimer's Association, a consortium of pharmaceutical companies and philanthropic foundations.
If you are a patient, family member, researcher or physician involved in Autosomal Dominant Alzheimer's disease, please use the Register link in the navigation bar at the top of the page. Once registered, we will contact you to describe the DIAN research trials. Your information is strictly confidential and is securely stored by the DIAN Expanded Registry. You may contact us to remove your information at any time.
Thank you for your time and commitment to Alzheimer’s disease research.